drugset / Trial / NCT02053103

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin

NCT02053103

Phase 2 Terminated 13 enrolled Pfizer
RandomizedParallel-groupDouble-blindBasic science

Summary

A Phase 2a study to evaluate the effects of an investigational compound administered at 200 mg, twice daily (BID), for 6 weeks in adult subjects with Type 2 Diabetes Mellitus (T2DM) on metformin background therapy.

Timeline

Start
2014-03
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-05175157 Small molecule 200 mg Oral